All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
• What are the side effects of MGD006?
• What is the highest dose of MGD006 that can be given safely?
• How long does MGD006 stay in the blood?
• How long does it take for MGD006 to leave the body?
• Is MGD006 a possible treatment for AML?
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination with Backbone Regimens for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
If you are eligible to participate in this study, you will be assigned to receive either:
1) Arm A: TAK-079 (study medication), lenalidomide and dexamethasone (backbone regimen)
2) Arm B: TAK-079 (study medication), bortezomib, lenalidomide and dexamethasone (backbone regimen)